COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION

1 . A method of inhibiting viral protein production in a host infected with a virus, comprising:

administering AR-12 to the host wherein viral protein production is reduced by at least about 50% compared to an untreated host.

2 . The method of claim 1 , wherein the viral protein is produced by influenza.

3 . The method of claim 2 , wherein the influenza virus is influenza A.

4 . The method of claim 2 , wherein the viral protein is structural protein.

5 . The method of claim 2 , wherein the viral protein is non-structural protein.

6 . A method of inhibiting viral replication in a host infected with a virus, comprising:

comprising administering AR-12 to the host in an amount sufficient to reduce viral replication in the host by at least about 50%.

7 . The method of claim 6 , wherein the virus is selected from the group consisting of a Group I virus, Group IV virus, Group V virus, and Group VII virus.

8 . The method of claim 6 , wherein the virus is selected from the group consisting of influenza, HIV, HIV-1, HIV-2, drug-resistant HIV, Junin virus, Chikungunya virus, Yellow Fever virus, Dengue virus, Pichinde virus, Lassa virus, adenovirus, Measles virus, Punta Toro virus, Respiratory Syncytial virus, Rift Valley virus, RHDV, SARS coronavirus, Tacaribe virus, and West Nile virus.

9 . The method of claim 6 , wherein AR-12 is provided to the host in an amount sufficient to achieve a blood, tissue, or organ concentration from about 0.1 μM to about 7 μM.

10 . A method of reducing viral infection in a host infected with Chikungunya virus comprising administering AR-12 to the host in an amount sufficient a blood, tissue, or organ concentration from of about 1 μM to 100 μM.

11 . The method of claim 10 , wherein the virus is a favipiravir-resistant strain of Chikungunya virus.

12 . A method of reducing viral infection in a host infected with Junin virus comprising administering AR-12 to the host in an amount sufficient to achieve a blood, tissue, or organ concentration of about 0.15 μM to 0.55 μM.

13 . A method of inhibiting retroviral replication in a host infected with a retrovirus, comprising administering AR-12 to the host in an amount sufficient to achieve a blood, tissue, or organ concentration of about 0.1 μM to about 20 μM.

14 . The method of claim 13 , wherein AR-12 is administered to the host in an amount sufficient to achieve a blood or tissue concentration of about 0.30 μM.

15 . The method of claim 13 , further comprising administering at least a second compound to the host.

16 . The method of claim 15 , wherein the second compound is selected from the group consisting of tipranavir, indinavir, atazanavir, saquinavir, lopinavir, ritonavir, darunavir, atazanavir, nelfinavir, emtricitabine, lamivudine {3TC}, zidovudine {AZT}, didanosine, tenofovir, stavudine, abacavir, rilpivirine, etravirine, nevirapine, delavirdine, efavirenz, T-20, maraviroc, raltegravir, and dolutegravir.

17 . A method of inhibiting replication of HIV DR in a host infected with HIV DR, comprising administering AR-12 to the host in an amount sufficient to achieve a blood, tissue, or organ concentration of at least about 0.30 μM.

18 . A method of increasing the survival rate of a host having viral-induced fulminant hepatic failure, comprising administering AR-12 to the host in an amount of at least about 25 mg/kg.

19 . The method of claim 18 , wherein AR-12 is administered to the host in amount of at least four doses of 25 mg/kg.

20 . The method of claim 19 , wherein the survival rate of the host is increased by at least about 20%.

21 . A method of reducing Dengue virus infection in a host infected with Dengue virus, comprising administering AR-12 to the host in an amount sufficient to achieve a blood, tissue, or organ concentration of at least about 1 μM.

22 . The method of claim 21 , wherein the blood, tissue, or organ concentration is at least about 4 μM.